Home Biosimilar Antibodies Apoptosis Others lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)
For research use only. Not for use in humans.

lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Synonyms: DR5， TNFRSF10B

Lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. MW : 145.5 KD.

lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Quality Control

Batch: A233001 Purity: 99% Protein concentration: 4.69mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. MW : 145.5 KD.

Product Details

CAS No. 845816-02-6
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06251544 NOT_YET_RECRUITING Breast Cancer; Tumor, Breast; Breast Tumor; Malignant Neoplasm of Breast; Mammary Cancer; Mammary Neoplasm; Mammary Neoplasms, Human; Neoplasm, Breast Baylor College of Medicine 2026-06 PHASE1
NCT02991196 TERMINATED Drug: DS-8273a + nivolumab Colorectal Neoplasm Daiichi Sankyo 2016-12-01 PHASE1
NCT00428272 TERMINATED Drug: Lexatumumab alone|Drug: Lexatumumab in combination|Dru Ewing's Sarcoma; Osteosarcoma; Neuroblastoma; Rhabdomyosarcoma National Cancer Institute (NCI) 2006-12-04 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-03-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.